Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN41,9342,09-0,19
Msft0,62
Nokia3,58853,6-0,14
IBM0,21
Daimler AG48,1948,211,03
PFE2,00
23.10.2020 23:28:24
Indexy online
AD Index online
select
AD Index online
 

  • 19.10.2020 14:45:36
Fate Therapeutics (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
41,20 8,06 3,00 2 472
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.10.2020
Popis společnosti
Obecné informace
Název společnostiFate Therapeutics Inc
TickerFATE
Kmenové akcie:Ordinary Shares
RICFATE.O
ISIN-
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 178
Akcie v oběhu k 03.08.2020 86 844 029
Počet akcionářů k 31.12.2019 35
MěnaUSD
Kontaktní informace
Ulice3535 General Atomics Ct Ste 200
MěstoSAN DIEGO
PSČ92121-1140
ZeměUnited States
Kontatní osobaRenee Leck
Funkce kontaktní osobyIR Contact Officer
Telefon18 588 751 803
Fax13026365454
Kontatní telefon12 123 621 200

Business Summary: Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Fate Therapeutics Inc revenues increased 46% to $8M. Net loss increased 42% to $61.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development increase of 36% to $47.3M (expense), Stock-based Compensation in R&D increase of 85% to $8.6M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 23.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardWilliam Rastetter71
President, Chief Executive Officer, DirectorJohn Wolchko49
Independent Vice Chairman of the BoardJohn Mendlein60
Chief Financial OfficerEdward Dulac4517.08.202017.08.2020
Senior Vice President - Clinical TranslationSarah Cooley-20.02.201920.02.2019
Chief Scientific OfficerDaniel Shoemaker52
Vice President - Clinical DevelopmentYu-Waye Chu-18.04.201918.04.2019
General Counsel and Corporate SecretaryCindy Tahl4701.01.2009
Chief Development OfficerBahram Valamehr43